Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

SHA:600535 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,603	2,994	4,451	3,119	2,304	1,976
Trading Asset Securities	886.32	524.72	300.71	1,125	1,487	142.92
Cash & Short-Term Investments	3,489	3,518	4,751	4,244	3,791	2,119
Cash Growth	-29.77%	-25.95%	11.95%	11.95%	78.94%	8.63%
Accounts Receivable	2,737	1,966	2,131	3,348	3,796	5,198
Other Receivables	35.79	23.06	11.49	8.98	9.47	421.43
Receivables	2,772	1,989	2,142	3,357	3,805	5,619
Inventory	1,429	1,712	1,748	1,532	1,548	1,354
Other Current Assets	109.31	91.72	91.43	127.08	105	145.92
Total Current Assets	7,800	7,311	8,733	9,260	9,249	9,237
Property, Plant & Equipment	3,502	3,648	3,769	3,883	4,088	3,881
Long-Term Investments	1,469	1,821	2,054	1,511	1,229	1,535
Goodwill	-	-	15.88	15.88	167.08	15.88
Other Intangible Assets	779.33	604.17	573.64	459.43	474.54	361.4
Long-Term Deferred Tax Assets	49.18	53.17	50	88.29	60.79	42.82
Long-Term Deferred Charges	1,306	1,466	1,476	1,157	1,193	1,412
Other Long-Term Assets	52.18	72.54	43.14	102.08	79.68	8.45
Total Assets	14,957	14,976	16,714	16,477	16,542	16,494
Accounts Payable	329.26	606.81	572.73	887.77	728.58	572.52
Accrued Expenses	240.01	171.05	178.38	242.79	213.15	200.28
Short-Term Debt	464.76	710.95	814.63	201.77	188.79	638.73
Current Portion of Long-Term Debt	166.3	586.83	462.74	475.21	343.33	1,137
Current Portion of Leases	-	47.84	58.54	53.98	55.67	-
Current Income Taxes Payable	138.78	57.78	18.04	84.62	108.09	34.6
Current Unearned Revenue	52.87	69.85	91.62	92.35	68.33	26.82
Other Current Liabilities	647.23	98.58	172.88	108.72	149.12	221.86
Total Current Liabilities	2,039	2,350	2,370	2,147	1,855	2,832
Long-Term Debt	178.84	253.76	1,414	1,376	1,034	1,020
Long-Term Leases	47.13	67.97	81.52	75.31	81.63	-
Long-Term Unearned Revenue	191.66	193.29	159.02	177.79	214.57	234.56
Long-Term Deferred Tax Liabilities	0.4	0.4	0.11	22.87	42.18	22.55
Total Liabilities	2,457	2,865	4,024	3,799	3,228	4,109
Common Stock	1,494	1,494	1,500	1,500	1,513	1,513
Additional Paid-In Capital	472.37	458.96	958.08	1,457	1,530	2,321
Retained Earnings	10,270	9,898	9,929	9,351	10,222	8,359
Treasury Stock	-	-	-105.98	-105.98	-251.29	-194.86
Comprehensive Income & Other	68.04	52.22	88	211.58	-32.19	-25.1
Total Common Equity	12,304	11,903	12,368	12,412	12,981	11,972
Minority Interest	195.66	207.86	321.59	265.12	332.56	411.77
Shareholders' Equity	12,500	12,111	12,690	12,678	13,314	12,384
Total Liabilities & Equity	14,957	14,976	16,714	16,477	16,542	16,494
Total Debt	857.03	1,667	2,831	2,182	1,704	2,796
Net Cash (Debt)	2,632	1,851	1,920	2,062	2,088	-677.47
Net Cash Growth	-5.91%	-3.59%	-6.89%	-1.23%	-	-
Net Cash Per Share	1.78	1.24	1.29	1.40	1.39	-0.45
Filing Date Shares Outstanding	1,487	1,494	1,494	1,494	1,499	1,503
Total Common Shares Outstanding	1,487	1,494	1,494	1,494	1,499	1,503
Working Capital	5,760	4,961	6,363	7,113	7,394	6,406
Book Value Per Share	8.28	7.97	8.28	8.31	8.66	7.97
Tangible Book Value	11,525	11,299	11,779	11,937	12,340	11,595
Tangible Book Value Per Share	7.75	7.56	7.88	7.99	8.23	7.71
Buildings	-	3,517	3,505	3,490	3,398	3,239
Machinery	-	3,763	3,625	3,472	3,340	2,974
Construction In Progress	-	221.76	153.87	102.96	167.85	400.97

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.